Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 77

Sort by

Sort Order Select

Journal Articles

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Blood (2024) 143 (2): 139–151.

https://doi.org/10.1182/blood.2022018658

Published: 2024

Includes: Supplemental data

Journal Articles

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Blood (2023) 142 (20): 1724–1739.

https://doi.org/10.1182/blood.2023020400

Published: 2023

Includes: Supplemental data

Journal Articles

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

Patrizia Porazzi, Yusuke Isshiki, Guido Ghilardi, Siena Nason, Ziqi Yang, Alberto Carturan, Linhui Chen, Yunlin Zhang, Ruchi P. Patel, Puneeth Guruprasad, Ositadimma Ugwuanyi, Ivan J Cohen, Stephen J Schuster, Ari M Melnick, Wendy BÃ©guelin, Marco Ruella

Blood (2023) 142 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2023-182440

Published: 2023

Journal Articles

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Yusuke Isshiki, Patrizia Porazzi, Xi Chen, Matthew Teater, Ioannis Karagiannidis, Henna S. Nam, Ari M Melnick, Marco Ruella, Wendy BÃ©guelin

Blood (2023) 142 (Supplement 1): 432.

https://doi.org/10.1182/blood-2023-190610

Published: 2023

Journal Articles

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

Blood (2023) 142 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2023-182234

Published: 2023

Journal Articles

Senza5 TM CART5 : An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity

Adam E. Snook, Ruchi P. Patel, Guido Ghilardi, Aditya Nimmagadda, Steven Yang, Dean Qian, Patrizia Porazzi, Rosemary Mazanet, Stephen J Schuster, Stefan K. Barta, Trang Vu, Marco Ruella, Nicholas A. Siciliano

Blood (2023) 142 (Supplement 1): 3462.

https://doi.org/10.1182/blood-2023-190386

Published: 2023

Journal Articles

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Adam D. Cohen, Wei-Ting Hwang, Sandra Susanibar-Adaniya, Dan T. Vogl, Alfred L. Garfall, Adam Waxman, Danielle Zubka, Chau Nguyen, Cynthia Diaczynsky, Marco Ruella, Michael C. Milone, Edward A. Stadtmauer

Blood (2023) 142 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2023-187409

Published: 2023

Journal Articles

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Ruchi P. Patel, Guido Ghilardi, Yunlin Zhang, Puneeth Guruprasad, Mathew G. Angelos, Raymone Pajarillo, Khatuna Gabunia, Chong Xu, Tatiana Blanchard, John Scholler, Patrizia Porazzi, Gerald Linette, Beatriz M. Carreno, Marco Ruella

Blood (2023) 142 (Supplement 1): 102.

https://doi.org/10.1182/blood-2023-186611

Published: 2023

Journal Articles

Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma

Benjamin Frost, Jennifer JD Morrissette, Stephen J Schuster, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, Elise A. Chong, Marco Ruella, Adam Bagg, Daniel J. Landsburg

Blood (2023) 142 (Supplement 1): 3518.

https://doi.org/10.1182/blood-2023-186553

Published: 2023

Journal Articles

Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer

Blood (2023) 142 (Supplement 1): 768.

https://doi.org/10.1182/blood-2023-189633

Published: 2023

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 2416.

https://doi.org/10.1182/blood-2023-187524

Published: 2023

Journal Articles

Precision Targeting of the Malignant Clone in Diffuse Large B Cell Lymphoma Using Chimeric Antigen Receptor T Cells Against the Clonotypic IGHV4-34 B Cell Receptor

Ivan J Cohen, Audrey C Bochi-Layec, Ki Hyun Kim, Scott Jenks, Ositadimma Ugwuanyi, Guido Ghilardi, Giulia Gabrielli, Jaryse Harris, Li-Ping Wang, Yunlin Zhang, Raymone Pajarillo, Elisavet Vlachonikola, Patrizia Porazzi, Ignacio Sanz, Paolo Ghia, Kostas Stamatopoulos, Stephen J Schuster, Marco Ruella

Blood (2023) 142 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2023-187618

Published: 2023

Journal Articles

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

Reid M. Muenzen, Emeline R. Chong, Dylan Therwhanger, Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, Mitchell E. Hughes, Elizabeth Weber, Marco Ruella, Noelle V. Frey, David L. Porter, Stephen J. Schuster, Elise A. Chong

Blood (2023) 142 (Supplement 1): 2341.

https://doi.org/10.1182/blood-2023-190434

Published: 2023

Journal Articles

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 2096.

https://doi.org/10.1182/blood-2023-189369

Published: 2023

Journal Articles

Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms

Mathew G. Angelos, Ruchi P. Patel, Yi-Hao Chiang, Wei Xie, Raymone Pajarillo, Carolyn E. Shaw, Ekta Singh, Jason Xu, Avery D. Posey, Alain Rook, Antonia Rotolo, Vinodh Pillai, Stefano A. Pileri, David T. Teachey, Marco Ruella

Blood (2023) 142 (Supplement 1): 885.

https://doi.org/10.1182/blood-2023-181282

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

CD5 Expression in Mature T Cell Lymphoma

Miao Cao, Montreh Tavakkoli, Elise A. Chong, Jordan S Carter, Marco Ruella, Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Stephen J Schuster, Stefan K. Barta

Blood (2023) 142 (Supplement 1): 6195.

https://doi.org/10.1182/blood-2023-188043

Published: 2023

Journal Articles

DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance

Nan Zhou, Jaewoo Choi, Grant Grothusen, Bang-Jin Kim, Diqiu Ren, Zhendong Cao, Yiman Liu, Qinglan Li, Arati Inamdar, Thomas Beer, Hsin-Yao Tang, Eric Perkey, Ivan Maillard, Roberto Bonasio, Junwei Shi, Marco Ruella, Liling Wan, Luca Busino

Blood (2023) 142 (11): 973–988.

https://doi.org/10.1182/blood.2022018752

Published: 2023

Includes: Supplemental data

Journal Articles

Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Blood (2022) 140 (Supplement 1): 7371–7373.

https://doi.org/10.1182/blood-2022-167601

Published: 2022

Journal Articles

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 4612–4614.

https://doi.org/10.1182/blood-2022-162393

Published: 2022

NARROW

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

Senza5 TM CART5 : An Autologous CD5-Deleted Anti-CD5 CART Product with Enhanced Anti-T-Cell Lymphoma Activity

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma

Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma

Precision Targeting of the Malignant Clone in Diffuse Large B Cell Lymphoma Using Chimeric Antigen Receptor T Cells Against the Clonotypic IGHV4-34 B Cell Receptor

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

CD5 Expression in Mature T Cell Lymphoma

DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance

Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only